Quarterly report
Open the filing on sec.gov
Silexion Therapeutics Corp (SLXN)
Nasdaq: SLXN · Biological Products, (No Diagnostic Substances) · Ramat Gan, IL · filing with the SEC since 2024
The companyfiscal 2025, as filed
Revenue$155,000+453.6%
Net income-$11.9M+27.9%
Earnings per share$8.96-97.7%
Operating cash flow-$10.8M-28.9%
Cash$6.1M+378.3%
Debtn/a
Shareholders’ equity$2.6M+165.3%
Shares, diluted1,329,515+17750.6%
Return on equity-457.6%
The recordfrom its filings
Filings in 202692
Newest filingNov 12 · 10-Q
Annual reportMar 17, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Revenue $133,000Net income -$13.2MCash from operations -$11.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.